Broker Radar for December


HSBC maintained ‘Buy’ on Biocon; hiked TP to Rs325 from Rs280.
  • Ogivri is well set to grab market share on flexible dosage offering, supported by Biocon’s robust manufacturing setup.
  • Gaining favourable formulary coverage will be a key factor for Ogivri’s success.
  • Biocon remains well placed to gain from a favourable push for biosimilars in regulated markets.
Macquarie maintained ‘Outperform’ on Zee Entertainment with a TP of Rs446.
  • Events over the past week to improve corporate governance and strengthen Zee’s balance sheet.
  • Most issues raised were known; management to work swiftly to restore investor confidence.
  • Investors would hope no further material negative surprises.
Morgan Stanley maintained ‘Overweight’ on Reliance Industries; hiked TP to Rs1,753.
  • With higher telecom tariffs, RIL’s Return on Capital Employed should rise above 10%.
  • See chemical margin trend reversing as supply rationalisation and demand pick-up.
  • Combined with asset monetisation and slowing investments, expect 25% FY20-F22 earnings per share compounded annual growth rate.
UBS maintained ‘Buy’ on SBI; hiked TP to Rs450 from Rs375.
  • IBC resolutions are likely to offset recent stress.
  • Three potential risks: telecom, NBFCs and mid-sized corporates.

About Gosip4U

Gosip4U is the digital wing of india - India's leading media and communications group with its interests spanning across country.


Post a Comment

Please add comment